636 related articles for article (PubMed ID: 31724441)
1. Inhibition of SARS-CoV 3CL protease by flavonoids.
Jo S; Kim S; Shin DH; Kim MS
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):145-151. PubMed ID: 31724441
[TBL] [Abstract][Full Text] [Related]
2. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro.
Jo S; Kim S; Kim DY; Kim MS; Shin DH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1539-1544. PubMed ID: 32746637
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors.
Jo S; Kim H; Kim S; Shin DH; Kim MS
Chem Biol Drug Des; 2019 Dec; 94(6):2023-2030. PubMed ID: 31436895
[TBL] [Abstract][Full Text] [Related]
4. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
5. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F
Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476
[TBL] [Abstract][Full Text] [Related]
6. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
Grum-Tokars V; Ratia K; Begaye A; Baker SC; Mesecar AD
Virus Res; 2008 Apr; 133(1):63-73. PubMed ID: 17397958
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.
Blanchard JE; Elowe NH; Huitema C; Fortin PD; Cechetto JD; Eltis LD; Brown ED
Chem Biol; 2004 Oct; 11(10):1445-53. PubMed ID: 15489171
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
Ghosh AK; Takayama J; Rao KV; Ratia K; Chaudhuri R; Mulhearn DC; Lee H; Nichols DB; Baliji S; Baker SC; Johnson ME; Mesecar AD
J Med Chem; 2010 Jul; 53(13):4968-79. PubMed ID: 20527968
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
Eur J Med Chem; 2013 Jul; 65():436-47. PubMed ID: 23747811
[TBL] [Abstract][Full Text] [Related]
11. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG
Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700
[TBL] [Abstract][Full Text] [Related]
12. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
[TBL] [Abstract][Full Text] [Related]
15. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
16. Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs.
Lin CW; Tsai CH; Tsai FJ; Chen PJ; Lai CC; Wan L; Chiu HH; Lin KH
FEBS Lett; 2004 Sep; 574(1-3):131-7. PubMed ID: 15358553
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase.
Gan YR; Huang H; Huang YD; Rao CM; Zhao Y; Liu JS; Wu L; Wei DQ
Peptides; 2006 Apr; 27(4):622-5. PubMed ID: 16242214
[TBL] [Abstract][Full Text] [Related]
18. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor design for SARS coronavirus main protease based on "distorted key theory".
Du QS; Sun H; Chou KC
Med Chem; 2007 Jan; 3(1):1-6. PubMed ID: 17266617
[TBL] [Abstract][Full Text] [Related]
20. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
Yang H; Bartlam M; Rao Z
Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
